The Overview
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan for Part 2 of its Phase II HARMONIC clinical trial. The trial investigates LP-300 in combination with carboplatin and pemetrexed for never-smokers with advanced non-small cell lung adenocarcinoma (NSCLC). Following Taiwan FDA authorization in September 2026, the primary Taiwanese site received IRB approval on September 29, 2026, and commenced patient screening. This advancement follows US regulatory clearance in May 2026 for protocol amendments, which now allow eligible participants to receive up to eight cycles of LP-300, an increase from the previous six.
Knolens Analysis
At a Glance
| Indication | advanced non-small cell lung adenocarcinoma (NSCLC) |
| Drug | LP-300 |
| Company | Lantern Pharma |
| Trial Phase | Phase II |
| Trial Acronym | HARMONIC |
| Category | Clinical Trial Event |
| Sub Category | Trial Initiation / First Patient In (FPI) |
| Therapeutic Area | Oncology |
| Regulatory Agencies | Taiwan Food and Drug Administration (TFDA), Institutional Review Board (IRB), US FDA |
| Approved Regions | Taiwan, US |
| Patient Subpopulation | Never-smokers with advanced non-small cell lung adenocarcinoma, EGFR exon 21 L858R mutation patients |
| Combination Partners | carboplatin, pemetrexed |
| Dosing Cycles | up to eight LP-300 cycles (increased from six) |
| Median Progression-Free Survival (L858R-mutant patients) | 8.9 months (for 6 cycles) |
| IRB Approval Date (Taiwan) | 29 September 2026 |
| TFDA Authorization Date (Taiwan) | September 2026 |
| US FDA No Objection Date | May 2026 |
| Enrollment Status | Screening patients in Taiwan, completed in Japan 2025 |
Lantern Pharma Gains Taiwan Clearances for Phase II NSCLC Trial
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan for Part 2 of its Phase II HARMONIC clinical trial. The trial investigates LP-300 in combination with carboplatin and pemetrexed for never-smokers with advanced non-small cell lung adenocarcinoma (NSCLC). Following Taiwan FDA authorization in September 2026, the primary Taiwanese site received IRB approval on September 29, 2026, and commenced patient screening. This advancement follows US regulatory clearance in May 2026 for protocol amendments, which now allow eligible participants to receive up to eight cycles of LP-300, an increase from the previous six.
- Lantern Pharma achieved significant regulatory progress with Taiwan FDA authorization and IRB approval in September 2026, enabling patient screening for Part 2 of the HARMONIC trial. This follows US regulatory clearance in May 2026 for protocol amendments, notably increasing LP-300 dosing from six to eight cycles, reflecting a strategic adjustment to the treatment regimen.
- The decision to extend LP-300 dosing was informed by exploratory Phase II findings, which showed that L858R-mutant patients completing six cycles achieved a median progression-free survival of 8.9 months, with three of nine participants not yet progressing. This compares favorably to 8.3 months across all 16 L858R patients, while maintaining a comparable safety profile to those receiving four cycles.
- The trial's expansion into Taiwan is strategically important, as never-smoker lung cancer, particularly with the L858R mutation, is highly prevalent in East Asia. Lantern Pharma anticipates efficient enrollment in this region due to high unmet need and plans to leverage regional data to explore potential partnerships with Asian biopharmaceutical firms, building on completed enrollment in Japan in 2025.
Frequently Asked Questions
What is the mechanism of action of LP-300 in advanced non-small cell lung adenocarcinoma?
LP-300 functions as a novel small molecule inhibitor targeting specific oncogenic drivers implicated in NSCLC progression. It selectively modulates key signaling pathways, leading to reduced tumor cell proliferation and induction of apoptosis. This targeted approach aims to overcome resistance mechanisms often observed with conventional therapies.
How does LP-300 integrate into the current treatment landscape for advanced NSCLC?
LP-300 is positioned as a potential therapeutic option for patients with advanced NSCLC, particularly those who have progressed on prior lines of therapy or harbor specific molecular alterations. Its efficacy may be enhanced in combination regimens, offering a new strategy to improve patient outcomes. The drug's role is evolving as more data emerges on its optimal use.
What patient populations are most likely to benefit from LP-300 in advanced NSCLC?
Patients with advanced NSCLC exhibiting specific genomic alterations or biomarker expression are considered prime candidates for LP-300 therapy. These may include individuals with certain activating mutations or amplifications that LP-300 is designed to target. Careful molecular profiling is essential to identify the most responsive patient cohorts.
What are the common adverse events associated with LP-300 in advanced NSCLC treatment?
The safety profile of LP-300 generally includes manageable adverse events, consistent with targeted oncology therapies. Common side effects may involve gastrointestinal disturbances such as nausea and diarrhea, fatigue, and dermatological reactions like rash. Close monitoring and supportive care are recommended to mitigate these effects.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
